Literature DB >> 29233903

Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients.

Marie-Nicole Theodoraki1,2,3, Saigopalakrishna S Yerneni4, Thomas K Hoffmann3, William E Gooding5, Theresa L Whiteside6,2,7.   

Abstract

Purpose: The microenvironment of head and neck squamous cell carcinomas (HNSCC) is highly immunosuppressive. HNSCCs expressing elevated levels of PD-L1 have especially poor outcome. Exosomes that carry PD-L1 and suppress T-cell functions have been isolated from plasma of patients with HNSCC. The potential contributions of PD-L1+ exosomes to immune suppression and disease activity are evaluated.Experimental Design: Exosomes isolated from plasma of 40 HNSCC patients by size exclusion chromatography were captured on beads using anti-CD63 Abs, stained for PD-1 and PD-L1 and analyzed by flow cytometry. The percentages and mean fluorescence intensities (MFI) of PD-L1+ and PD-1+ exosome/bead complexes were correlated with the patients' clinicopathologic data. PD-L1high or PD-L1low exosomes were incubated with activated CD69+ human CD8+ T cells ± PD-1 inhibitor. Changes in CD69 expression levels on T cells were measured. Patients' plasma was tested for soluble PD-L1 (sPD-L1) by ELISA.
Results: Levels of PD-L1 carried by exosomes correlated with patients' disease activity, the UICC stage and the lymph node status (P = 0.0008-0.013). In contrast, plasma levels of sPD-L1 or exosome PD-1 levels did not correlate with any clinicopathologic parameters. CD69 expression levels were inhibited (P < 0.03) by coincubation with PD-L1high but not by PD-L1low exosomes. Blocking of PD-L1+ exosome signaling to PD-1+ T cells attenuated immune suppression.Conclusions: PD-L1 levels on exosomes, but not levels of sPD-L1, associated with disease progression in HNSCC patients. Circulating PD-L1+ exosomes emerge as useful metrics of disease and immune activity in HNSCC patients. SIGNIFICANCE: Circulating PD-L1high exosomes in HNC patients' plasma but not soluble PD-L1 levels associate with disease progression. Clin Cancer Res; 24(4); 896-905. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29233903      PMCID: PMC6126905          DOI: 10.1158/1078-0432.CCR-17-2664

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  39 in total

Review 1.  Tumor-Derived Exosomes and Their Role in Cancer Progression.

Authors:  Theresa L Whiteside
Journal:  Adv Clin Chem       Date:  2016-04-07       Impact factor: 5.394

Review 2.  Exosomes and tumor-mediated immune suppression.

Authors:  Theresa L Whiteside
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 4.  Basics of PD-1 in self-tolerance, infection, and cancer immunity.

Authors:  Shunsuke Chikuma
Journal:  Int J Clin Oncol       Date:  2016-02-10       Impact factor: 3.402

5.  CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression.

Authors:  A Risso; D Smilovich; M C Capra; I Baldissarro; G Yan; A Bargellesi; M E Cosulich
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

6.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

8.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

9.  Tissue expression of PD-L1 mediates peripheral T cell tolerance.

Authors:  Mary E Keir; Spencer C Liang; Indira Guleria; Yvette E Latchman; Andi Qipo; Lee A Albacker; Maria Koulmanda; Gordon J Freeman; Mohamed H Sayegh; Arlene H Sharpe
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

Review 10.  PD-L1 expression in human cancers and its association with clinical outcomes.

Authors:  Xin Wang; Feifei Teng; Li Kong; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

View more
  191 in total

Review 1.  Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.

Authors:  Colin Sheehan; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2019-10-15       Impact factor: 5.285

Review 2.  The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2018-11-09       Impact factor: 5.225

3.  Role of extracellular vesicles in stem cell biology.

Authors:  Stefania Bruno; Giulia Chiabotto; Enrica Favaro; Maria Chiara Deregibus; Giovanni Camussi
Journal:  Am J Physiol Cell Physiol       Date:  2019-05-15       Impact factor: 4.249

4.  Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth.

Authors:  Yi Yang; Chia-Wei Li; Li-Chuan Chan; Yongkun Wei; Jung-Mao Hsu; Weiya Xia; Jong-Ho Cha; Junwei Hou; Jennifer L Hsu; Linlin Sun; Mien-Chie Hung
Journal:  Cell Res       Date:  2018-06-29       Impact factor: 25.617

5.  Identification and characterization of an alternative cancer-derived PD-L1 splice variant.

Authors:  Nadia B Hassounah; Venkat S Malladi; Yi Huang; Samuel S Freeman; Ellen M Beauchamp; Shohei Koyama; Nicholas Souders; Sunil Martin; Glenn Dranoff; Kwok-Kin Wong; Chandra S Pedamallu; Peter S Hammerman; Esra A Akbay
Journal:  Cancer Immunol Immunother       Date:  2018-12-18       Impact factor: 6.968

Review 6.  Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application.

Authors:  Zhen Zhao; Jia Fan; Yen-Michael S Hsu; Christopher J Lyon; Bo Ning; Tony Y Hu
Journal:  Lab Chip       Date:  2019-03-27       Impact factor: 6.799

7.  Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type.

Authors:  Ji-Wei Li; Ping Wei; Ye Guo; Di Shi; Bao-Hua Yu; Yi-Fan Su; Xiao-Qiu Li; Xiao-Yan Zhou
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

8.  Separation of plasma-derived exosomes into CD3(+) and CD3(-) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients.

Authors:  M-N Theodoraki; T K Hoffmann; T L Whiteside
Journal:  Clin Exp Immunol       Date:  2018-03-12       Impact factor: 4.330

Review 9.  Mechanisms Controlling PD-L1 Expression in Cancer.

Authors:  Jong-Ho Cha; Li-Chuan Chan; Chia-Wei Li; Jennifer L Hsu; Mien-Chie Hung
Journal:  Mol Cell       Date:  2019-10-24       Impact factor: 17.970

Review 10.  The Microenvironment of Tongue Cancer.

Authors:  Want Tao; Zeng Li-Juan; Li Kan; Li Jing-Yuan; Liu Xiang-Qi; Liang Yu-Jie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.